All In Biotech

Drug Trial Radar · NCT05270213

Evaluation of RBS2418 in Subjects With Advanced, Metastatic Solid Tumors

A First-In-Human, Phase 1 a/b Dose Escalation and Expansion Study to Evaluate RBS2418 as Monotherapy and in Combination With Pembrolizumab in Subjects With Advanced Unresectable, Recurrent or Metastatic Tumors

Last checked: Nov 19, 2026Latest source record: Dec 19, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

164

Planned (sponsor's estimate)

Start

Jul 11, 2022

Primary completion

Apr 2027

Study completion Dec 2027

Sponsor

Lead sponsor
Riboscience, LLC.Industry
Sponsor type
Industry
First posted
Mar 8, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

RBS2418 (investigational product) is a specific immune modulator, working through ectonucleotide pyrophosphatase/phosphodiesterase I (ENPP1), designed to lead to anti-tumor immunity by increasing endogenous 2'-3'-cyclic guanosine monophosphate-adenosine monophosphate (cGAMP) and adenosine triphosphate (ATP levels) and reducing adenosine production in the tumors. RBS2418 has the potential to be an important therapeutic option for subjects both as monotherapy and in combination with other cancer treatments including monotherapy and in combination with other cancer treatments including immunotherapy or chemotherapy. This study is an open-label, multi-site Phase 1a/1b study of RBS2418, a selective ENPP1 inhibitor, in combination with pembrolizumab or other approved anticancer therapies or as a monotherapy in subjects with advanced unresectable, recurrent or metastatic tumors. The phase 1a (dose escalation phase) has been completed. The Phase 1b expansion phase of the study has been increased in size and scope.

Conditions

  • Advanced Cancer

Interventions

  • RBS2418Drug

    RBS2418 is a potent and selective small molecule inhibitor of ectonucleotide pyrophosphatase/phosphodiesterase I (ENPP1). RBS2418 as monotherapy potentially can have an activating effect on the anti-tumor innate immune response and lead to anti-tumor responses in adult subjects with advanced or metastatic tumors.

  • PembrolizumabDrug

    200 mg intravenously every 3 weeks

  • Other approved anti-cancer therapyDrug

    Standard of care (SOC) therapy

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Treatment emergent dose limiting toxicities (DLT)Time frame: From 1- 21 days of the first cycle (each cycle is 21 days)
  2. Peak plasma concentration (Cmax) of RBS2418Time frame: Day 0 - 5
  3. Area under the plasma concentration versus time curve (AUC)Time frame: Day 0 - 5
  4. Optimal Biologically Active Dose (OBA)Time frame: Day 0 - 5
  5. Half-life (t1/2)Time frame: Day 0 - 5
  6. Number of participants with treatment emergent Adverse eventsTime frame: 30 days from last dose

Locations

14 sites in 1 country. Site status is shown where the registry gives one.

  • Honor Health Research Institute

    Scottsdale, Arizona · Recruiting

  • University of Arizona

    Tucson, Arizona · Recruiting

  • Stanford Cancer Institute

    Palo Alto, California · Recruiting

  • UCLA Hematology/Oncology - Santa Monica

    Santa Monica, California · Recruiting

  • Christiana Care Health Services

    Newark, Delaware · Recruiting

  • Norton Cancer Institute

    Louisville, Kentucky · Recruiting

  • Ochsner Clinic Foundation

    New Orleans, Louisiana · Recruiting

  • Johns Hopkins Sidney Kimmel Comprehensive Cancer Center

    Baltimore, Maryland · Recruiting

  • American Oncology Partners of Maryland

    Bethesda, Maryland · Recruiting

  • Ichan School of Medicine at Mount Sinai

    New York, New York · Recruiting

  • Carolina BioOncology Institute

    Huntersville, North Carolina · Completed

  • Vanderbilt-Ingram Cancer Center

    Nashville, Tennessee · Recruiting

  • Tranquil Research

    Webster, Texas · Withdrawn

  • NEXT Virigina

    Fairfax, Virginia · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.